8-K - STEX - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported): November 30, 2023

BioSigTechnologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-38659	26-4333375
(State<br> or other jurisdiction	(Commission	(IRS<br> Employer
of<br> incorporation)	File<br> Number)	Identification<br> No.)
55 Greens Farms Road, 1st Floor<br><br> <br>Westport, Connecticut	06880
---	---
(Address<br> of principal executive offices)	(Zip<br> Code)

(203)409-5444

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common<br> Stock, par value $0.001 per share	BSGM	The<br> NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements ofCertain Officers.

Effective as of November 30, 2023 (the “Grant Date”), the board of directors (the “Board”) of BioSig Technologies, Inc. (the “Company”) granted awards of restricted stock pursuant to the Company’s 2023 Long-Term Incentive Plan (the “Plan”) to certain named executive officers of the Company in connection with a temporary reduction of 30% of their salaries.

The Board granted to (i) Kenneth L. Londoner, Chief Executive Officer of the Company, 219,700 restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) John R. Sieckhaus, Chief Operating Officer of the Company, 92,300 restricted shares of Common Stock (collectively, the “RSAs”), subject to the terms and conditions of the Company’s Plan and the Company’s standard Restricted Stock Award Agreement. The RSAs fully vested on the Grant Date.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIOSIG TECHNOLOGIES, INC.
Date:<br> December 5, 2023	By:	/s/ Kenneth L. Londoner
	Name:	Kenneth<br> L. Londoner
	Title:	Executive<br> Chairman